U.S. biotechnology company Moderna plans to invest more than $500 million in a vaccine and drug manufacturing facility in Kenya.
Leaders of the African nation signed a memorandum of understanding with Moderna on Monday in the capital Nairobi.
The new facility will help address the problem of vaccine inequity experienced across Africa.
Kenyan President Uhuru Kenyatta said African countries faced challenges during the COVID-19 pandemic because vaccines were not available for them to purchase.
The state-of-the-art mRNA facility will focus on drug substance manufacturing.
It is expected to produce up to 500 million doses of vaccines each year.